Doximity
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Trade Doximity 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About DOCS
Doximity, Inc. engages in the development and operation of an online platform for medical professionals. Its cloud-based software has the ability to enable users to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.
CEOJeffrey A. Tangney
CEOJeffrey A. Tangney
Employees830
Employees830
HeadquartersSan Francisco, California
HeadquartersSan Francisco, California
Founded2010
Founded2010
Employees830
Employees830
DOCS Key Statistics
Market cap10.17B
Market cap10.17B
Price-Earnings ratio49.88
Price-Earnings ratio49.88
Dividend yield—
Dividend yield—
Average volume1.89M
Average volume1.89M
High today$59.00
High today$59.00
Low today$53.35
Low today$53.35
Open price$57.00
Open price$57.00
Volume5.71M
Volume5.71M
52 Week high$85.21
52 Week high$85.21
52 Week low$47.66
52 Week low$47.66
Stock Snapshot
Doximity(DOCS) stock is priced at $54.33, giving the company a market capitalization of 10.17B. It carries a P/E multiple of 49.88.
On 2025-11-08, Doximity(DOCS) stock traded between a low of $53.35 and a high of $59.00. Shares are currently priced at $54.33, which is +1.8% above the low and -7.9% below the high.
Doximity(DOCS) shares are trading with a volume of 5.71M, against a daily average of 1.89M.
In the last year, Doximity(DOCS) shares hit a 52-week high of $85.21 and a 52-week low of $47.66.
In the last year, Doximity(DOCS) shares hit a 52-week high of $85.21 and a 52-week low of $47.66.
Analyst ratings
52%
of 21 ratingsBuy
52.4%
Hold
38.1%
Sell
9.5%
People also own
Based on the portfolios of people who own DOCS. This list is generated using Robinhood data, and it’s not a recommendation.